Short-Term Efficacy of Tegoprazan Compared With Esomeprazole in Patients With Non-Erosive Reflux Disease and Nocturnal Heartburn Symptoms: A Double-Blind, Randomized Controlled Trial
Abstract
Objectives: Tegoprazan is a novel potassium-competitive acid blocker that rapidly suppresses acid secretion. This study aimed to evaluate the efficacy of tegoprazan 50 mg compared with esomeprazole 20 mg in patients with non-erosive reflux disease and nocturnal heartburn symptoms. Methods: This double-blind, randomized, active-control study was conducted to compare the efficacy of tegoprazan 50 mg and esomeprazole 20 mg in patients with non-erosive reflux disease and nocturnal heartburn symptoms. The primary endpoint was the percentage of nocturnal heartburn-free days over 2 weeks. The secondary endpoint was the percentage of patients who experienced relief from nocturnal heartburn within 24 h of the first dose. Additionally, the time to the first nocturnal heartburn-free interval was compared between the two groups. Results: Of 160 patients, 149 were included in the final analysis. The percentage of nocturnal heartburn-free days over 2 weeks was not inferior to that with esomeprazole (58.2% vs. 54.5%, p=0.001). The percentage of patients without nocturnal heartburn for 24 h was higher in the tegoprazan group, although the difference was not statistically significant. The time to the first nocturnal heartburn-free interval was shorter with tegoprazan than with esomeprazole (2.0 days vs. 2.5 days, p=0.529); however, the difference was not significant. Conclusions: Tegoprazan demonstrated non-inferiority to esomeprazole with respect to nocturnal heartburn-free days and may…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 160 participants or records.
Read the paper
Related studies
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study
- Occupation and risk of severe COVID-19: prospective cohort study of 120,075 UK Biobank participants
- Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study
- Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study
- Lifestyle risk factors, inflammatory mechanisms, and COVID-19 hospitalization: A community-based cohort study of 387,109 adults in UK
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.